✦ LIBER ✦

Efficacy and safety of donepezil in patients with dementia with Lewy bodies: Preliminary findings from an open-label study

✍ Scribed by SATORU MORI; ETSURO MORI; EIZO ISEKI; KENJI KOSAKA

Book ID: 108961961
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 138 KB
Volume: 60
Category: Article
ISSN: 1323-1316
DOI: 10.1111/j.1440-1819.2006.01485.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rivastigmine in the treatment of dementi

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial

✍ Ian G. McKeith; Janet B. Grace; Zuzana Walker; E. Jane Byrne; David Wilkinson; T 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

The objective of this study was to assess the tolerability and efficacy of rivastigmine in a group of patients with probable dementia with Lewy bodies (DLB), using an open label study. Open label treatment was with rivastigmine up to maximum tolerated dose (mean 9.6 mg daily, range 3-12 mg). Eleven

What happens when donepezil is suddenly

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia

✍ Thaís S. C. Minett; Alan Thomas; Lucy M. Wilkinson; Sarah L. Daniel; Jonathan Sa 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

## Abstract ## Background This open label study was designed to assess the effects of donepezil treatment, its withdrawal and subsequent recommencement on cognitive functioning, behaviour and parkinsonian symptoms in patients with probable dementia with Lewy bodies (DLB) and with Parkinson's disea

Efficacy and safety of donepezil over 3

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease

✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##

OPEN LABEL TRIAL TO EVALUATE THE EFFICAC

OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF YOKUKANSAN, A TRADITIONAL ASIAN MEDICINE, IN DEMENTIA WITH LEWY BODIES

✍ Koh Iwasaki; Kenji Kosaka; Hideo Mori; Reina Okitsu; Katsutoshi Furukawa; Yuta M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Better cognitive and psychopathologic re

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

✍ William Samuel; Michael Caligiuri; Douglas Galasko; Jonathan Lacro; Merri Marini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

In several retrospective post-mortem studies, patients meeting clinical criteria for Alzheimer's disease (AD) who gained the greatest cognitive bene®t from treatment with an acetylcholinesterase (AChE) inhibitor were found to have neocortical Lewy bodies accompanying classical AD neuropathology. Thi

Long term safety and efficacy of donepez

Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study

✍ V. P. Prasher; C. Adams; R. Holder 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views